Cover Image

Multi-center outcome analysis of 16 face transplantations - a retrospective OPTN study

Facial Vascularized Composite Allotransplantation (fVCA) restores form and function for patients with severe facial disfigurements, yet multi-center outcome data remain scarce. We accessed the Organ Procurement and Transplantation Network (OPTN) database from 2008-2024 to identify all full- or parti...

Full description

Saved in:
Bibliographic Details
Main Authors: Knoedler, Leonard (Author) , Schaschinger, Thomas (Author) , Niederegger, Tobias (Author) , Hundeshagen, Gabriel (Author) , Panayi, Adriana C. (Author) , Cetrulo, Curtis L. (Author) , Jeljeli, Maxime (Author) , Hofmann, Elena (Author) , Heiland, Max (Author) , Koerdt, Steffen (Author) , Lellouch, Alexandre G. (Author)
Format: Article (Journal)
Language:English
Published: January 2025
In: Transplant international
Year: 2025, Volume: 38, Pages: 1-12
ISSN:1432-2277
DOI:10.3389/ti.2025.14107
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/ti.2025.14107
Verlag, kostenfrei, Volltext: https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.14107/full
Get full text
Author Notes:Leonard Knoedler, Thomas Schaschinger, Tobias Niederegger, Gabriel Hundeshagen, Adriana C. Panayi, Curtis L. Cetrulo, Maxime Jeljeli, Elena Hofmann, Max Heiland, Steffen Koerdt and Alexandre G. Lellouch
Description
Summary:Facial Vascularized Composite Allotransplantation (fVCA) restores form and function for patients with severe facial disfigurements, yet multi-center outcome data remain scarce. We accessed the Organ Procurement and Transplantation Network (OPTN) database from 2008-2024 to identify all full- or partial-face fVCA recipients, excluding patients under 18 years and those with physiologically impossible BMIs. Of 25 identified patients, 16 (64%) met inclusion criteria (69% male; mean age 43 ± 14 years). Recipients experienced a median of 5 [IQR 0.0-10] acute rejection episodes, which correlated with inotrope use during donor procurement (p=0.033). On average, patients were hospitalized 2.4 ± 1.8 times, with arginine vasopressin (AVP) administration linked to fewer hospitalizations (p=0.035). Seven recipients (44%) experienced complications, and extended-criteria donor (ECD) status was associated with higher complication rates (p=0.049). These findings underscore the promise of fVCA to address complex facial defects while identifying key risk factors—particularly inotrope use and ECD status, while AVP administration may mitigate hospital stays. Further studies with larger cohorts are warranted to refine perioperative strategies, improve outcomes, and expand the clinical utility of fVCA.
Item Description:Veröffentlicht: 29. Januar 2025
Gesehen am 01.08.2025
Physical Description:Online Resource
ISSN:1432-2277
DOI:10.3389/ti.2025.14107

Similar Items